Figure 2
Figure 2. Simulation of rituximab serum levels with APO/Mediware Version 3.50. Depicted are the simulated median concentration profile of rituximab (black line) and the 90% CI (upper and lower 5th percentile over 100; dotted lines). The pharmacokinetics model is based on mean values of pharmacokinetics parameters as follows: Cl = 9.9 mL/h, V1 (l/kgLBMc) = 4.39 l, Vdss = 12.8 l, t1/2α = 8.47h, and t1/2β = 896 hours (37 days) of 20 patients treated with R-CHOP-14 according to a 2-compartment model. LBMc indicates lean body mass corrected.

Simulation of rituximab serum levels with APO/Mediware Version 3.50. Depicted are the simulated median concentration profile of rituximab (black line) and the 90% CI (upper and lower 5th percentile over 100; dotted lines). The pharmacokinetics model is based on mean values of pharmacokinetics parameters as follows: Cl = 9.9 mL/h, V1 (l/kgLBMc) = 4.39 l, Vdss = 12.8 l, t1/2α = 8.47h, and t1/2β = 896 hours (37 days) of 20 patients treated with R-CHOP-14 according to a 2-compartment model. LBMc indicates lean body mass corrected.

Close Modal

or Create an Account

Close Modal
Close Modal